Message from the President

My name is Hiroshi Nomura, and I have the honor of serving as Representative Director, President and CEO of Sumitomo Pharma Co., Ltd.

In October 2005, Sumitomo Pharmaceuticals Co., Ltd. and Dainippon Pharmaceutical Co., Ltd. merged under the trade name Sumitomo Dainippon Pharma Co., Ltd. During the 16 and a half years since the merger, we have undergone a major transformation. We have globalized our business, entered new research areas, and taken on numerous challenges such as large-scale acquisitions and partnerships. For us to grow continuously and evolve toward a new business stage, we have changed the name of the company from "Sumitomo Dainippon Pharma" to "Sumitomo Pharma," on April 1st, 2022.

Sumitomo Pharma Group operates every day to achieve its Mission "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By directing our efforts into the research and development of new drugs, we aim to provide innovative and valuable pharmaceutical and healthcare solutions to people not only in Japan but also around the world to realize our Mission.

With a focus on the Psychiatry & Neurology and Oncology disease areas, where unmet medical needs are high, the Sumitomo Pharma Group will continue making active efforts for research and development of new modalities such as regenerative medicine/cell therapy and non-pharmaceutical solutions in addition to pharmaceuticals. In other areas, too, we will tap into assets at hand and make steady R&D efforts to deliver solid value to patients. In addition, we are engaged in business activities with the goal of becoming the number one company in diabetes in Japan.

Through these efforts, we will aim to become a "Global Specialized Player" whose presence is felt throughout the world.

We will also engage in a wide range of other initiatives, including active dialog with diverse stakeholders such as patients, their families, healthcare professionals, our shareholders, other investors, employees, business partners, and the local communities in which we work; social contribution activities in and outside Japan; and promotion of diversity and inclusion. At the same time, by strengthening our corporate governance system and thoroughly ensuring compliance in the conduct of our business, we will continuously enhance our corporate value and thereby contribute to the creation of a more sustainable society.

All Sumitomo Pharma Group executives and employees to work together with a single purpose of doing our best work to earn and maintain the trust of our stakeholders and continue to be a company that delivers better health and well-being.

On behalf of all of us at Sumitomo Pharma, I would like to sincerely thank you for your ongoing support and encouragement.

Hiroshi Nomura

Representative Director,
President and Chief Executive Officer
Sumitomo Pharma Co., Ltd.

(As of August 2023)